FN1 and neoplasm: An antibody‐cytokine conjugate targeting a tumor‐associated fibronectin epitope to enable local distribution of tumor necrosis factor was associated with increasing tumor necrosis and local inflammation in a phase I study, with objective responses in 3/5 progressive GBM patients, and is currently being evaluated in further trials [171, 172].